Study Details
Setanaxib with a 52-week Extension Phase in Patients with Primary Biliary Cholangitis (PBC) and Elevated Liver Stiffness
(IRB#: IRB_00151228)
To evaluate the effect of setanaxib on biochemical response at Week 52 in patients with PBC and with elevated liver stiffness and intolerance or inadequate response to UDCA
- All genders
- Over 18 years old
- Volunteers with special conditions
- In Person
- Paid
Who can participate?
Gender: All genders
Age: Over 18 years old
Volunteers: Volunteers with special conditions
Location: In Person
Will I be paid for my time?
Yes
IRB#: IRB_00151228
PI: Shaun Chandna
Department: GASTROENTEROLOGY
Approval Date: 2022-03-23 06:00:00
Specialties: Gastroenterology